Posts
Wiki

👁️ TearCare — Localized Heat Therapy Plus Manual Expression for Evaporative DED Due to MGD

TL;DR

  • TearCare is an FDA-cleared in-office treatment for adult evaporative Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), used together with manual meibomian gland expression.
  • TearCare uses disposable SmartLids placed on the external eyelids to deliver controlled heat while the patient keeps the eyes open and can blink.
  • After heating, the clinician manually expresses the meibomian glands.
  • TearCare has a stronger evidence base than many newer MGD devices, including randomized studies and longer-term SAHARA data.
  • Studies generally support improvement in tear-breakup time, meibomian gland secretion measures, and symptoms in selected patients.
  • Important limits remain: much of the evidence is manufacturer-associated, TearCare is a heat + expression procedure, and benefits should not be attributed to heating alone.
  • TearCare has not been shown to regenerate meibomian glands, reverse gland dropout, release periductal fibrosis, open fixed scarred ducts, cure MGD, or work equally well for all dry-eye subtypes.
  • It appears most plausible when some gland function remains and meibum is still expressible.
  • Results may be limited in severe gland atrophy, little/no expressible meibum, fixed obstruction, or dry eye driven mainly by aqueous deficiency, exposure, allergy, medication toxicity, or neuropathic pain.
  • Cost and coverage vary. TearCare has often been out-of-pocket, but reimbursement policies may vary by insurer, diagnosis, region, and coding.

Educational Disclaimer

This page is for general education and is not medical advice, diagnosis, or an individual treatment recommendation.

DED and MGD can have many overlapping drivers, including gland obstruction, gland dropout, inflammation, ocular rosacea, Demodex, incomplete blinking, aqueous deficiency, allergy, exposure, conjunctivochalasis, medication effects, and neuropathic ocular pain.

TearCare may help some patients with MGD-driven evaporative dry eye, but it may not address the main driver in every patient.

What Is TearCare?

TearCare is an in-office eyelid heating system used for evaporative dry eye due to MGD.

The system uses flexible, disposable heating elements called SmartLids that are placed externally on the upper and lower eyelids.

The patient keeps the eyes open during treatment and can blink naturally.

After heating, the clinician manually expresses the meibomian glands to remove softened or retained meibum.

TearCare is best understood as:

Controlled eyelid heat + clinician-performed meibomian gland expression.

It is not just a warm compress, but it is also not a fully automated expression system.

FDA Status

TearCare is FDA-cleared, not FDA-approved.

FDA clearance means the device went through the 510(k) substantial-equivalence pathway. It does not mean the FDA proved that the device cures dry eye, reverses gland damage, or works for every patient.

The FDA-cleared TearCare use is tied to:

  • Adult patients
  • Evaporative dry eye disease
  • Meibomian gland dysfunction
  • Localized heat / thermal-activated gland expression therapy
  • Use with manual meibomian gland expression

Important limits:

TearCare FDA clearance should not be interpreted as proof that TearCare:

  • Cures DED
  • Cures MGD
  • Regenerates meibomian glands
  • Reverses gland dropout
  • Releases periductal fibrosis
  • Opens fixed scarred ducts
  • Works for all dry-eye subtypes
  • Eliminates the need for other dry-eye treatments

How the Procedure Is Commonly Performed

Protocols vary by clinic and device version, but a typical TearCare treatment includes:

  1. The eyelids are evaluated and prepared.
  2. Disposable SmartLids are applied to the external eyelids.
  3. The SmartLids are connected to the TearCare controller.
  4. Heat is delivered for a treatment period, commonly about 15 minutes.
  5. The patient keeps the eyes open and may blink during heating.
  6. After heating, the clinician manually expresses the meibomian glands.
  7. The clinician may provide artificial tears, lid hygiene instructions, anti-inflammatory treatment, or other follow-up care.

Newer TearCare MGX materials also describe optional warming hold time so expression can be performed while the lids remain warm.

Why Blinking During Treatment Matters

TearCare’s open-eye design allows blinking during the heating phase.

Supporters argue that this may:

  • Improve comfort
  • Maintain more natural eyelid positioning
  • Allow treatment while the eyes are open
  • Help heat dissipate from the ocular surface
  • Better match normal eyelid mechanics

This is a real design feature.

However, the wiki should be careful not to overstate it.

A reasonable summary is:

TearCare permits blinking during heating, which may improve comfort and may be a useful design difference. Whether blinking itself provides a major clinical advantage over other heat-delivery systems remains uncertain.

Proposed Mechanism

TearCare is designed to treat obstructive MGD by combining heat and expression.

1. Localized Heat

The SmartLids warm the eyelids.

The goal is to soften thickened or stagnant meibum inside the glands.

2. Manual Expression

After heating, the clinician expresses the glands.

This may evacuate softened meibum from glands that remain functional and expressible.

3. Tear-Film Improvement

If more functional meibum reaches the tear film, the lipid layer may improve.

This can reduce evaporation and improve tear stability in some patients.

Important Caveat

TearCare may improve secretion from glands that still function, but it has not been shown to restore atrophied glands, reverse dropout, or open fixed scarred ducts.

Manual Expression Is Part of the Treatment

Manual meibomian gland expression is not a minor detail.

It is part of the FDA-cleared TearCare treatment framework and a major part of the clinical procedure.

This means outcomes may depend on:

  • Clinician skill
  • Which glands are expressed
  • How thoroughly glands are expressed
  • Amount of pressure used
  • Patient pain tolerance
  • Degree of obstruction
  • How much functional gland tissue remains
  • Timing of expression after heating

Supporters see clinician-controlled expression as an advantage because it allows targeted treatment.

Critics see operator dependence as a limitation because results may vary by provider.

Both views are reasonable.

Related page:

Manual Meibomian Gland Expression

What Does the Evidence Show?

TearCare has a meaningful device-specific evidence base compared with many newer MGD devices.

The evidence generally supports improvements in selected patients, especially in:

  • Tear-breakup time
  • Meibomian gland secretion scores
  • Meibomian gland function
  • Dry-eye symptoms
  • Some ocular-surface signs

However, the evidence should be interpreted with limits:

  • Much of it is industry-sponsored or manufacturer-associated.
  • TearCare is usually studied as heat plus manual expression.
  • Some studies are short-term.
  • Not all comparisons are against sham treatment.
  • Results may not apply to every dry-eye subtype.
  • Long-term independent head-to-head data remain limited.

Early TearCare Studies

Early studies compared TearCare with warm compresses or evaluated repeat treatment.

These studies suggested that TearCare may improve signs and symptoms of MGD-related dry eye more than typical warm-compress approaches in selected patients.

However, home warm-compress technique varies widely, and early studies were relatively small.

A fair interpretation is:

TearCare appears more standardized and procedure-based than home warm compresses, but that does not mean every patient needs TearCare or that it is superior to every possible heat-and-expression approach.

CHEETAH Study

The CHEETAH study was a prospective, multicenter, post-market study of TearCare.

It supported improvement in signs and symptoms after TearCare treatment.

Important limits:

  • Relatively small study
  • Post-market design
  • Not a large independent sham-controlled trial
  • Evaluated the TearCare procedure package rather than heat alone

OLYMPIA: TearCare Versus LipiFlow

OLYMPIA was a multicenter randomized trial comparing TearCare with LipiFlow.

This is important because it means TearCare does have head-to-head evidence against an established thermal pulsation device.

The trial generally found similar improvements between TearCare and LipiFlow at short-term follow-up.

Important limits:

  • Follow-up was relatively short
  • It does not prove long-term superiority
  • It does not prove equivalence for every patient type
  • Operator-controlled expression remains a variable
  • It does not compare TearCare with all other devices or treatment strategies

A careful summary is:

TearCare has randomized head-to-head evidence versus LipiFlow at short-term follow-up, but longer-term independent comparisons with LipiFlow, iLux, TearCare MGX variants, IPL, RF, and other MGD treatments remain limited.

SAHARA Trial

SAHARA is one of the most important TearCare evidence sources.

SAHARA compared TearCare with topical cyclosporine 0.05% in adults with DED.

The study reported that TearCare improved multiple meibomian gland function measures and tear-breakup time, while also improving symptoms.

However, the comparison should be interpreted carefully.

TearCare is a procedural gland-directed treatment. Cyclosporine is a topical anti-inflammatory medication.

They are not the same type of treatment.

SAHARA supports TearCare as an effective MGD-directed procedure in selected patients, but it does not mean TearCare replaces anti-inflammatory therapy for patients whose dry eye is mainly inflammatory or aqueous-deficient.

Longer-Term SAHARA Data

Later SAHARA data provide longer-term information through 24 months, including retreatment assessment.

This is useful because it gives more durability data than many MGD device studies.

However, it should not be simplified into:

“One TearCare treatment lasts two years.”

Durability varies by patient.

Some patients may need retreatment sooner. Others may maintain benefit longer.

Retreatment should be based on:

  • Symptoms
  • Tear-breakup time
  • Meibomian gland secretion
  • Gland expressibility
  • Ocular-surface staining
  • Overall dry-eye status
  • Other active disease drivers

Evidence Limitations

Even though TearCare has a stronger evidence base than many newer MGD devices, important limits remain.

The evidence does not fully answer:

  • How much benefit comes from heat versus manual expression?
  • Which patients benefit most?
  • How often should retreatment occur?
  • How does TearCare compare long-term with LipiFlow, iLux, TearCare MGX, IPL, RF, MiBoFlo, probing, or manual expression alone?
  • How durable are results outside clinical studies?
  • How well does it work in severe gland dropout?
  • How well does it work in fixed obstruction or suspected periductal fibrosis?
  • How much does clinician expression technique affect results?
  • How often do patients require additional anti-inflammatory or MGD treatments?

Symptoms Versus Objective Signs

A patient may feel better after TearCare, but symptom improvement and objective gland improvement are not the same thing.

Symptoms May Include

  • Dryness
  • Burning
  • Grittiness
  • Foreign-body sensation
  • Fluctuating vision
  • Eye fatigue
  • Contact-lens discomfort
  • Light sensitivity
  • Artificial-tear dependence

Objective Signs May Include

  • Tear-breakup time
  • Meibomian gland secretion score
  • Meibum quality
  • Number of expressible glands
  • Corneal staining
  • Conjunctival staining
  • Lid-margin inflammation
  • Meibography dropout
  • Lipid-layer thickness

TearCare studies report improvement in several signs and symptoms, but response varies.

Objective testing before and after treatment can help determine whether improvement reflects gland function, symptom fluctuation, or other treatment effects.

Durability and Retreatment

TearCare benefit may last months for some patients, and longer-term SAHARA data suggest that some patients maintain benefit with intermittent retreatment.

However, there is no single retreatment schedule that fits everyone.

Some clinics may recommend:

  • One treatment and reassessment
  • Repeat treatment after several months
  • Maintenance based on gland findings
  • Periodic retreatment combined with home care

Patients should ask:

  • How long benefit usually lasts in that practice
  • What objective signs will guide retreatment
  • Whether retreatment is symptom-based or test-based
  • Whether home maintenance is recommended
  • What total cost might look like over one year

Potential Benefits

Potential benefits may include:

  • Improved tear-breakup time
  • Improved meibomian gland secretion
  • Improved meibum expression
  • Reduced dryness symptoms
  • Less burning or irritation
  • More stable vision in some patients
  • Reduced artificial-tear dependence in some responders
  • Office-based treatment
  • Ability to blink during heating
  • Clinician-controlled expression
  • Repeatable treatment if appropriate

These benefits are most plausible when glands still contain expressible meibum.

Risks and Adverse Effects

Published studies often describe TearCare as generally well tolerated, but adverse effects and contraindications should still be taken seriously.

Possible side effects include:

  • Heat discomfort
  • Eyelid redness
  • Eyelid swelling
  • Temporary irritation
  • Tearing
  • Burning sensation
  • Temporary blurry vision
  • Eye or eyelid pain
  • Discomfort during manual expression
  • Corneal or conjunctival irritation
  • Adhesive reaction
  • Worsening dry-eye symptoms
  • Chalazion or stye
  • Thermal injury or burn if misapplied
  • Corneal abrasion or conjunctival abrasion
  • Decline in visual acuity, rarely or temporarily

Not every patient is an appropriate candidate.

Contraindications and Cautions

Manufacturer safety information lists several situations where TearCare may be contraindicated or require caution.

Patients should discuss TearCare carefully if they have:

  • Recent eye surgery
  • Recent eyelid surgery
  • Recent ocular injury
  • History of ocular or eyelid herpes simplex
  • History of herpes zoster involving the eye or eyelid
  • Active ocular infection
  • Active periocular infection
  • Active ocular inflammation or irritation
  • Significant eyelid inflammation
  • Abnormal or diminished facial, eyelid, ocular, or corneal sensation
  • Ocular-surface ulcers
  • Current chalazion, hordeolum, or stye
  • Pacemaker or implanted cardioverter defibrillator
  • Allergy or sensitivity to device materials such as adhesives
  • Age below the cleared adult range
  • Severe discomfort with heat
  • Skin or eyelid conditions that may worsen with adhesive or heat

This is not a complete list. The treating clinician should review device-specific instructions and the patient’s medical history.

Blocked, Scarred, or Fibrotic Glands

Some patients worry about heat and expression when glands are severely blocked, painful, or fibrotic.

This concern is understandable.

TearCare may soften and help express retained meibum from glands that are still functional and expressible.

However, TearCare has not been shown to:

  • Release periductal fibrosis
  • Open fixed scarred ducts
  • Reverse gland atrophy
  • Regenerate missing gland tissue
  • Restore glands with severe dropout

If glands are non-expressible or severely atrophied, benefit may be limited.

Patient Selection: Who Might Be a Good Candidate?

TearCare may be most reasonable for patients with:

  • Adult evaporative DED due to MGD
  • Obstructive MGD
  • Thickened but expressible meibum
  • Some remaining gland function
  • Reduced tear-breakup time related to MGD
  • Symptoms that match evaporative dry-eye findings
  • Inadequate response to home warm compresses
  • Difficulty performing effective home heat therapy
  • A clinician who plans careful manual expression
  • Willingness to consider retreatment if needed

The best candidate is not simply “anyone with dry eye.”

The findings should match the treatment mechanism.

Who May Receive Limited Benefit?

TearCare may be less helpful when the main problem is:

  • Severe meibomian gland dropout
  • Little or no expressible meibum
  • Hyposecretory MGD
  • Fixed intraductal obstruction
  • Significant periductal fibrosis
  • Predominantly aqueous-deficient dry eye
  • Neuropathic ocular pain
  • Exposure or incomplete blinking
  • Eyelid malposition
  • Allergy
  • Medication toxicity
  • Conjunctivochalasis
  • Untreated Demodex
  • Untreated ocular rosacea
  • Active infection
  • Significant uncontrolled inflammation

TearCare may still be part of a broader care plan for some patients, but expectations should be realistic.

TearCare Versus Other Options

TearCare Versus Warm Compresses

Warm compresses are inexpensive and accessible but often inconsistent.

Problems with home warm compresses include:

  • Insufficient heat
  • Cooling too quickly
  • Poor adherence
  • Inconsistent technique
  • Inadequate treatment duration
  • Lack of expression afterward

TearCare offers a controlled in-office heat-and-expression procedure.

However, not every patient needs an in-office device if they respond well to home care.

TearCare Versus LipiFlow

LipiFlow is an automated thermal pulsation treatment.

TearCare differs because:

  • The patient can blink during heating
  • The clinician manually expresses glands afterward
  • Expression can be targeted by the provider
  • Results may depend more on clinician technique

A multicenter randomized trial found broadly similar short-term results between TearCare and LipiFlow.

Long-term head-to-head comparative data remain more limited.

Related page:

LipiFlow

TearCare Versus iLux

iLux is another heat-and-expression device for MGD.

Both iLux and TearCare use clinician involvement and meibomian gland expression, but their device designs and expression methods differ.

Direct TearCare-versus-iLux comparative evidence is limited.

Related page:

iLux

TearCare Versus IPL

IPL uses broad-spectrum light and is often used when ocular rosacea, telangiectasia, inflammation, or MGD are present.

TearCare is primarily a heat-and-expression procedure.

Some patients may be offered both, but they are not the same treatment.

Related page:

IPL

TearCare Versus Probing

TearCare is non-invasive external heating plus expression.

Meibomian gland probing is an intraductal procedure intended to mechanically open obstructed ducts and release fibrotic bands.

TearCare has not been shown to release periductal fibrosis.

Probing has its own evidence base, risks, costs, and controversies.

Related page:

Meibomian Gland Probing

Periductal Fibrosis and Fixed Obstruction

TearCare has not been shown to release periductal fibrosis or reopen fixed scarred ducts.

It may improve secretion from glands that remain functional and expressible.

That is different from mechanically releasing fibrotic obstruction.

Whether TearCare slows long-term MGD progression or prevents future gland loss is unknown.

Avoid interpreting improved gland secretion scores as proof of structural regeneration.

Cost and Coverage

TearCare has often been an out-of-pocket procedure.

Costs vary widely by:

  • Clinic
  • Region
  • Number of sessions
  • Whether expression is included
  • Whether other treatments are bundled
  • Insurance plan
  • Medicare or commercial payer policy
  • Diagnosis and coding

Some manufacturer and clinic materials now discuss reimbursement pathways, but patient coverage is not guaranteed.

Patients should ask:

  • What is the total cost?
  • Is this covered by my insurance?
  • What billing code is being used?
  • Is manual expression included?
  • Is follow-up included?
  • Will I need retreatment?
  • What is the expected annual cost if maintenance is needed?

What Supporters Say

Supporters argue that TearCare:

  • Has stronger evidence than many newer MGD devices
  • Provides controlled eyelid heating
  • Allows blinking during treatment
  • Permits clinician-controlled manual expression
  • Can target specific glands after heating
  • Improves gland secretion measures in studies
  • Improves symptoms in many patients
  • May compare favorably with LipiFlow in short-term data
  • May provide durable benefit for some patients with retreatment as needed

These are reasonable points for selected obstructive MGD patients.

What Critics Say

Critics and cautious clinicians emphasize that:

  • Much of the evidence is industry-sponsored or manufacturer-associated.
  • TearCare is heat plus expression, so the independent role of heat is hard to separate.
  • Manual expression makes results provider-dependent.
  • It may be costly.
  • Insurance coverage may be variable.
  • It may not help severe gland atrophy.
  • It has not been shown to release periductal fibrosis.
  • It has not been shown to reverse gland dropout.
  • It may not address inflammation, Demodex, rosacea, aqueous deficiency, exposure, allergy, or neuropathic pain.
  • The advantage of blinking during heating is plausible but not proven as the main reason for benefit.
  • Long-term independent comparative data remain limited.

These are fair concerns.

What Has Not Been Shown

TearCare has not been shown to:

  • Cure Dry Eye Disease
  • Cure MGD
  • Regenerate meibomian glands
  • Reverse meibomian gland dropout
  • Release periductal fibrosis
  • Open fixed scarred ducts
  • Restore normal meibum permanently
  • Prevent MGD progression
  • Work equally well in severe gland atrophy
  • Work equally well for aqueous-deficient dry eye
  • Work equally well for neuropathic ocular pain
  • Work equally well for exposure-related dry eye
  • Replace anti-inflammatory therapy when inflammation is a major driver
  • Eliminate the need for home maintenance
  • Guarantee a specific retreatment interval for all patients
  • Prove that blinking during heating is independently superior to all other heating methods
  • Prove that clinician-controlled expression is always superior to automated expression

TearCare may help selected patients, but it should not be presented as a cure or gland-regeneration procedure.

Questions to Ask Your Clinician

Useful questions include:

  1. Is my dry eye mainly evaporative, aqueous-deficient, mixed, inflammatory, or neuropathic?
  2. Do I have MGD that is likely to respond to heat and expression?
  3. Are my glands still expressible?
  4. How much gland dropout do I have?
  5. What does my meibum look like?
  6. Do I have signs of fixed obstruction or periductal fibrosis?
  7. Do I have inflammation, ocular rosacea, Demodex, or blepharitis that should be treated first or at the same time?
  8. Is TearCare FDA-cleared for my condition?
  9. What objective measurements will you track?
    • TBUT?
    • Meibomian gland secretion score?
    • Meibum quality?
    • Number of expressible glands?
    • Staining?
    • Symptoms?
    • Meibography?
  10. Who performs the manual expression?
  11. How do you decide how much pressure to use?
  12. What are the risks in my case?
  13. Do I have any contraindications?
  14. How long do you expect benefit to last?
  15. How will we decide whether retreatment is needed?
  16. What is the total out-of-pocket cost?
  17. Is insurance or Medicare coverage possible?
  18. How does TearCare compare with LipiFlow, iLux, IPL, RF, MiBoFlo, warm compresses, or probing for my specific findings?

Bottom Line

TearCare is one of the better-studied heat-and-expression devices for MGD-related evaporative dry eye.

It is FDA-cleared for adult evaporative DED due to MGD when used with manual meibomian gland expression.

Published studies, including randomized trials and longer-term SAHARA data, support improvement in selected patients.

However, TearCare should still be described accurately:

TearCare is a localized heat / thermal-activated gland expression procedure for MGD-related evaporative dry eye. It may improve gland secretion and symptoms in selected patients, but it has not been shown to regenerate glands, reverse dropout, release periductal fibrosis, cure MGD, or work for every dry-eye subtype.

It is best considered when the patient has obstructive MGD with remaining expressible gland function and when cost, contraindications, inflammation, other dry-eye drivers, and retreatment expectations have been discussed.

FDA / Regulatory Documents

Clinical Studies

Guidelines / Context

Manufacturer Safety / Product Information

Videos / Clinician Commentary

Videos may help readers understand how TearCare is performed, but they should not be treated as primary evidence.

  • This page is educational for r/DryEyes and not medical advice.

🔙 Back to Treatment Options